117 results about "Controlled drugs" patented technology

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

The invention discloses a self-driven diagnosis and treatment integrated microneedle array paper-based chip as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The microneedle array chip system comprises a function integration module which at least comprises a self-powered extraction unit, a sensing detection unit and a controlled drug delivery unit. According to the microneedle array paper-based chip, biomarkers in skin interstitial fluid are efficiently collected based on a self-powered thermoelectric chemical battery microneedle, PtPB (at) PEG (at) HA nanoparticles loaded on an immunochromatography test strip combination pad are triggered to be subjected to ring opening, a hybridization chain reaction is induced to generate DNA nano-enzyme, and TMB is catalyzed to develop color; the open-loop nanoparticles can be used for SERS cross detection of biomarkers, and can be used as a thermal initiator to activate the phase change microneedle under the irradiation of near-infrared light, so that drugs are released as required, and precise treatment is realized. Besides, objective quantitative analysis of color signals is realized by constructing a convolutional neural network model, and the system has the functions of naked eye screening, intelligent quantification and personalized treatment, and can improve the home management ability of early skin cancer.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention discloses a thiochromanone derivative containing a thiosemicarbazone structure and application of the thiochromanone derivative, relates to the technical field of medicines, and particularly relates to the technical field that the compound has better oxidation resistance and alpha-glucosidase resistance activity, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to ABTS clearance activity is 2.86 [mu] g / mL, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to alpha-glucosidase inhibition activity is 9.51 [mu] g / mL, and the effect is the best and is superior to that of a control agent vitamin E and acarbose. The thiochromanone derivative containing the thiosemicarbazone structure has a general formula shown in the specification,

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention relates to the technical field of organic chemistry, and particularly discloses an amide derivative containing a thiazole oxime structure as shown in a general formula 8 and a preparation method and application of the amide derivative. The derivative shows remarkable antibacterial activity on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa and fluoroquinolone-resistant escherichia coli, particularly has a remarkable effect on gram-negative bacteria, has broad-spectrum antibacterial potential and can be used for preparing drugs for treating related bacterial infection, and the activity of part of compounds is superior to that of a control drug.

Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment.In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a controlled drug-to-antibody ratio (DAR) to a target site.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

This invention provides a liquid composition for topical and transdermal drug delivery, comprising a polymethacrylate at >5% weight, a humectant, a plasticizer, and a solvent. Optionally, it includes a permeation enhancer and / or a drug. Upon application and rapid drying, the composition forms a durable, non-sticky, non-transferable film that enables controlled drug release through the skin or retention at the skin surface.

The method comprises the following steps: preparing a first test solution, a second test solution, a third test solution, a reference medicinal material solution and a reference substance solution, sampling the solutions on a silica gel G thin-layer plate, and identifying notopterygium root, radix angelicae pubescentis, ligusticum, ligusticum wallichii, divaricate saposhnikovia root and liquorice. According to the identification method of the notopterygium root-containing dampness-clearing decoction, the first test solution for simultaneously identifying notopterygium root, radix angelicae pubescentis, ligusticum and ligusticum wallichii, the second test solution for identifying divaricate saposhnikovia root and the third test solution for identifying liquorice are obtained through a specific extraction process, so that the detection efficiency is greatly improved.

The invention provides composite hydrogel, photo-thermal response drug release composite hydrogel as well as a preparation method and application of the photo-thermal response drug release composite hydrogel, and belongs to the technical field of biomedical materials. The hydrogel is constructed by taking methylacryloyl gelatin as a matrix and combining lauric acid microspheres carrying an osteogenesis promoting drug baicalin, a reduced graphene oxide photothermal agent and a photoinitiator LAP. Under the irradiation of near-infrared light, the hydrogel can realize local mild temperature rise, induce the lauric acid microspheres to generate solid-liquid phase change, release the entrapped osteogenesis promoting drug as required, realize the synergistic effect of photothermal therapy and controlled release of the drug, and have a good osteogenesis repair effect. The hydrogel has good mechanical properties, biocompatibility and degradability, can be used for local treatment of bone defect parts, and effectively promotes regeneration and repair of oral and maxillofacial bone tissues. The invention provides a novel controllable and efficient treatment thought for bone tissue engineering and regenerative medicine.

The invention belongs to the technical field of medicines, and particularly relates to a tanshinone and salvianolic acid compound molecular compatibility composition for regulating and controlling the balance relation of DNMTs / TET2 and application of the tanshinone and salvianolic acid compound molecular compatibility composition. An in-vitro cell model proves that the composition with specific compatibility can synergistically regulate the expression of DNMTs and TET2 and recover the balance relation of DNMTs and TET2, so that the abnormal DNA methylation state is reversed, the normal expression of related genes is recovered, and the composition can be used for preparing the medicine for preventing or treating cardiovascular diseases related to DNA methylation abnormity. The molecular compatibility composition for balance regulation and control of key targets is created for the first time, has the advantages of clear component compatibility, clear action targets and synergistic interaction, and provides a new choice for developing novel epigenetic regulation and control drugs.

The invention discloses a method for photocatalytic synthesis of a 2, 3-dihydrobenzopyran-4-ketone compound and application of the 2, 3-dihydrobenzopyran-4-ketone compound, a triplet excitation state with a double-free-radical characteristic is formed after photoexcitation of a chromone compound, and the triplet excitation state can be subjected to hydrogen atom transfer with various substrates such as ethers, esters, alcohols, alkanes, sulfides, amines and aryl phosphine compounds, so that the 2, 3-dihydrobenzopyran-4-ketone compound is obtained. And carrying out Giese addition on the generated free radicals and an unexcited chromone compound to obtain a target product. Further biological activity evaluation shows that part of products obtained in the invention show good inhibitory activity on tobacco mosaic viruses, and the good protective activities of target compounds 3i and 4b are 67.77% and 63.63% respectively when the concentration is 500mg / L, which are equivalent to 63.83% of a control drug ningnanmycin. Therefore, the compound not only is green and efficient in synthesis method, but also has potential application value in the aspects of agricultural disease control and structure protection research.

The application discloses a kind of controlled drug information query method and system, it is related to drug query technical field;Image data of controlled drug is acquired, and search area in cloud database is determined according to image data;Spectrum image uploaded by detection equipment is acquired, image preprocessing is carried out on spectrum image to obtain target spectrum image, numerical conversion is carried out on target spectrum image to obtain target feature set;Fuzzy search is carried out in search area according to target feature set to obtain feature sequence set;The similarity of each feature sequence in feature sequence set is calculated to obtain feature sequence intersection, and feature sequence intersection is used as accurate search direction to obtain matching result;Matching result is sent to detection equipment.Through image recognition and spectrum analysis, the above process efficiently narrows the search range, accurately extracts target features, accurately matches after fast fuzzy screening, and significantly improves the detection efficiency and accuracy of controlled drugs.

The invention belongs to the technical field of medical materials, and particularly relates to an electric controlled drug release metal organic framework based composite patch as well as a preparation method and application thereof. The preparation method comprises the following steps: growing UiO-67 on SWCNT in situ to prepare UiO (at) SWCNT, then carrying out N-methylation on a bipyridine part by using methyl trifluoromethanesulfonate to prepare UiO-N + (at) SWCNT, loading a small molecule drug to obtain UiO-N + (at) SWCNT / Dug, forming the electric controlled drug release metal organic framework based composite patch with P (PLMA-AM-DAC) hydrogel and a flexible printed circuit board, and connecting with a mobile phone APP through a Bluetooth module to prepare the electric controlled drug release metal organic framework based composite patch. And constructing the integrated electrical stimulation transdermal drug delivery application. The flexible wearable characteristic of the system enables the system to be more comfortable and convenient, the treatment compliance and life quality of a patient can be improved, and an intelligent solution is provided for chronic skin disease treatment.

The present disclosure relates generally to bioactive releasing membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the disclosure relates to novel bioactive releasing membranes, to devices and implantable devices including these membranes, methods for forming the bioactive releasing membranes on or around the implantable devices, and to methods for monitoring analyte levels in a biological fluid sample using an implantable analyte detection device.

The invention provides a preparation method of a cyanidin-3-O-glucoside-methyl sorbate acylated derivative, and belongs to the technical field of natural product modification. The method comprises the following steps: by taking cyanidin-3-O-glucoside as a substrate and methyl sorbate as an acyl donor, reacting in a low-toxicity DMF / tert-butyl alcohol (9: 1) mixed solvent under the catalysis of lipase Novozym 435, and extracting and purifying to obtain a target product. The C3G is modified by methyl sorbate containing conjugated double bonds, so that the fat solubility of the product is remarkably improved while the natural light response characteristic is reserved. A reaction system and a purification process method are optimized, the used acyl structure is more innovative, the reaction condition is mild, the conversion rate is high, few byproducts are produced, and the method is green and environment-friendly. Methyl sorbate is grafted to cyanidin-3-O-glucoside, so that the thermal stability of cyanidin-3-O-glucoside can be enhanced, the fat solubility can be improved, the problem that a light function is damaged by traditional acylation is solved, and a new raw material is provided for light-controlled drug delivery and weather-resistant food pigments.

The invention discloses a preparation method and application of a graded delivery system which takes a pH response type metal organic framework material NH2-MIL-101 (Fe) as a carrier and takes antibacterial peptide AMP and irisin as active ingredients. The graded delivery system comprises a metal organic framework material NH2-MIL-101 (Fe), AMP (adenosine monophosphate) and Irisin, wherein the AMP and the Irisin are loaded on the pH (potential of hydrogen) response type metal organic framework material NH2-MIL-101 (Fe). According to the system, aiming at periodontal and dental pulp infectious diseases, early-stage AMP rapid release for precise bacteriostasis and middle-stage Irisin synergistic release are realized through time sequence regulation and control to achieve anti-inflammatory and anti-oxidation effects, so that alveolar bone tissue / dentin regeneration is further promoted, and an excellent'antibacterial-anti-inflammatory-hard tissue regeneration 'cascade treatment effect is shown. The invention provides a new strategy and theoretical basis for precise treatment of periodontitis and pulpitis.

This invention provides an antibacterial and repair-promoting piezoelectric film, its preparation method, and its application, belonging to the field of piezoelectric material technology. The method involves in-situ self-assembly of Fe-MOF on the surface of BTO, followed by further loading with DHA to synthesize an electrically controlled drug-release, antibacterial, and repair-promoting nanocomposite, BTO / Fe-MOF / DHA. BTO / Fe-MOF / DHA is then added to the surface of semi-cured PDMS to form an antibacterial and repair-promoting piezoelectric film, PDMS-BTO / Fe-MOF / DHA. When the PDMS-BTO / Fe-MOF / DHA piezoelectric film is subjected to ultrasonic stimulation, BTO converts mechanical energy into electrical energy, releasing Fe from the Fe-MOF... 3+ Reduced to Fe 2+ Fe-MOF degrades and releases DHA, and ultimately, Fe... 2+ Reacting with synchronously released DHA, it produces a large amount of toxic ROS, which damages proteins and nucleic acids, inducing bacterial death. The antibacterial and repair-promoting piezoelectric membrane of the present invention generates a piezoelectric potential during mechanical deformation caused by animal movement and induces EF at the wound site to promote wound healing. This antibacterial and repair-promoting piezoelectric membrane shows great potential in the future treatment of bacterial infected wounds.

This invention relates to the field of medical device technology and provides a flexible self-powered oral diagnostic and treatment device and its preparation method. The device includes a flexible conductive porous microneedle, a flexible microfluidic module, a flexible triboelectric nanogenerator, and a flexible transparent dental crown. The flexible conductive porous microneedle is used to extract gingival crevicular fluid, and its surface has multiple rings of needles at different heights. The flexible microfluidic module incorporates a microchannel structure and a detection unit to analyze biomarkers in the gingival crevicular fluid. The flexible triboelectric nanogenerator converts the mechanical energy of oral motion into electrical energy to provide exogenous electrical stimulation and achieve electrically controlled drug release. This device enables real-time monitoring, diagnosis, and treatment of the oral microenvironment, and has advantages such as self-powered operation, good fit, and discreet comfort, making it suitable for closed-loop management of oral diseases such as periodontitis.

A new antibacterial peptide of Japanese eel A1 Cath2b 143‑174 and its application, belong to the field of biotechnology. The antibacterial peptide is a Cathelicidin family antibacterial peptide of Japanese eel A1 The 143-174 amino acid fragment of Cathelicidin 2b is named as Cath2b A1 Cath2b 143‑174 , and the amino acid sequence is shown as SEQ ID NO. 3. The antibacterial peptide has high inhibition / killing activity on various aquatic pathogenic bacteria, has excellent thermal stability and salt ion tolerance, and has no obvious toxicity to host cells; it plays a bactericidal role by destroying the bacterial cell membrane, and can also attract host immune cells to enhance immunity. The antibacterial peptide can be applied in the preparation of aquatic animal bacterial disease prevention and control drugs. It can solve the problems of drug resistance and drug residue caused by the abuse of traditional antibiotics, and is convenient to prepare, has strong adaptability, and is suitable for the prevention and control of bacterial diseases of aquatic animals.

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The present invention provides a photopolymerisable composition for 4D printing, comprising an acrylated polyol (AOPO) derived from a natural oil, such as olive oil, and acrylic acid as a comonomer. The composition is used in a solvent-free digital light processing (DLR) method to fabricate high-resolution, multifunctional objects. The resulting 4D printed objects are biocompatible, hemocompatible, and cytocompatible. They exhibit excellent temperature- responsive shape memory properties activated near body temperature, inherent antimicrobial activity against both gram-negative and gram-positive bacteria, and tuneable mechanical properties suitable for soft tissue engineering. Furthermore, the composition can be loaded with therapeutic agents, such as progesterone, to form biodegradable objects capable of sustained, controlled drug release. These properties make the material ideal for medical implants, cardiovascular stents, and drug delivery devices.

A drug delivery device may include a component with a bonding location to be bonded to a surface of one or more teeth. A cavity may hold a formulation that includes a compound, and an orifice may release the compound outside the component.

Controlled Drug Recording Book - Paperback

Provided are a nano-injection, and a preparation method therefor and a use thereof. The nano-injection has good stability, a controllable particle size, and a narrow particle size distribution range; and the nano-injection can be used for intravenous injection, acts rapidly, can effectively control drug burst release during injection, ensures steady drug release, provides a long duration of action, exhibits an excellent analgesic effect, and offers good safety.

This divisional application discloses the use of a 2,8-bis(trifluoromethyl)-4-hydroxyquinoline derivative in the control or treatment of agricultural pathogenic bacteria. The structural formula of the 2,8-bis(trifluoromethyl)-4-hydroxyquinoline derivative is as follows: Bioactivity tests show that this derivative exhibits excellent inhibitory activity against two plant bacteria: rice bacterial blight pathogen and citrus canker pathogen. Compound Q-29 shows an MIC90 value of 1.56 μg / mL against both rice bacterial blight pathogen and citrus canker pathogen, significantly outperforming the control drugs thiabendazole and thiabendazole copper. The compounds involved in this invention are easy to prepare, use inexpensive and readily available raw materials, and are expected to be developed into a novel agricultural antibacterial agent.

A composition of fluticasone / linezolid-loaded nanodiamond / polyacrylonitrile nanofibers, consisting of: • Fluticasone propionate in a quantity of 25 mg to 100 mg; • Linezolid in a quantity of 25 mg to 100 mg; • Nanodiamonds dispersed in a concentration of approximately 1 mg / ml dimethylformamide (DMF); and • a polyacrylonitrile (PAN) polymer matrix prepared as a 10% w / v solution in DMF, wherein the drugs, nanodiamonds and PAN are uniformly combined to form an electrospinnable nanocomposite solution, and electrospinning is carried out under conditions suitable for producing nanofibers with controlled drug release, porosity and structural integrity for wound healing applications.

The invention provides application of a compound HLF1-11 in preparation of a medicine for preventing and controlling magnaporthe oryzae and a medicine for inhibiting spore germination of the magnaporthe oryzae, and further provides a pesticide and a method for preventing and controlling the magnaporthe oryzae. The compound HLF1-11 has an obvious inhibiting effect on development of magnaporthe oryzae appressorium, can effectively inhibit pathogenicity of magnaporthe oryzae spores and can prevent and treat magnaporthe oryzae, so that a foundation is laid for research and development of related prevention and control drugs.

The embodiments herein provide shape-transforming pharmaceutical compositions and modular kits for the treatment of soft and hard tissue injuries, bone and joint defects, tendon and ligament repair, and surgical or organ exposures. The compositions comprise sterile, dry adsorbent composite polymer particles that are hydrated in situ with a sterile liquid containing one or more pharmaceutical agents. Hydration causes the particles to aggregate and transform into a conforming, shape-retentive device that provides extended coverage and sustained or controlled drug release. Kits enable powders and liquids to be applied sequentially or simultaneously, allowing tailored therapy at the point of care. Therapeutic agents may include antimicrobial, anti-inflammatory, hemostatic, regenerative, or analgesic compounds. These devices retain structure for extended durations, support customizable release kinetics, and may serve as a temporary implant to protect tissue while delivering localized therapy. The invention provides a versatile platform for prolonged, modular drug delivery across clinical and surgical settings.